Skip to main content

Table 5 Overview of all significant correlations per genetic variant

From: Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

Gene Variant allele (rs number, nucleotide) Effect of the variant allele on toxicity or outcome Corrected p value, adjusted OR, 95% CI Effect of the polymorphisms according to the literature
ABCB1 rs1128503 c.1236C > T Increased risk anemia grade 3-4 p = 0.023; Homozygous mutant allele carriers: decreased doctaxel clearance in 92 patients 9
OR 1.71, 1.07 – 2.71
ABCC2 rs12762549 g.101620771C > G Decreased risk anemia grade 3-4 p = 0.004; Japanese mutant allele carriers: increased risk for severe neutropenia during treatment with docetaxel in 84 patients19
OR 0.51, 0.33-0.81
rs2073337 c.1668 + 148A > G Decreased need for colony stimulating factor p = 0.039; In vitro evidence: paclitaxel is a substrate of ABCC224
OR 0.60, 0.37-0.98
ABCC1 rs2074087 c.2284-30 G > C Increased need for erythropoiesis stimulating agent p = 0.011; In vitro evidence: resistance to paclitaxel with ABCC1 overexpression23
OR 2.09, 1.18-3.68
ABCA1 rs363717 c.1896 A > G Increased risk anemia grade 3-4 p = 0.002; Mutant allele carriers: decreased risk to develop thalidomide related neuropathy grade ≥2 in 1495 patients 36
OR 2.08, 1.32-3.27
CYP3A4 rs4986910 c.1331 T > C Increased risk thrombocytopenia grade 3-4 p = 0.025; -
OR 4.99, 1.22-20.31
GSTP1 rs1695 c.313A > G Decreased need for colony stimulating factor p = 0.017; Mutant allele carriers: decreased oxaliplatin-related neuropathy in 90 patients30, decreased docetaxel-induced grade 2 neuropathy in 58 patients31, decreased risk of hematologic toxicity in 118 patients15
OR 0.55, 0.33-0.90 Heterozygous mutant allele carriers compared to homozygous wildtype allele carriers: decreased PFS following cisplatin-gemcitabine in 104 patients 32
ERCC1 rs11615 c.354 T > C Increased risk anemia grade 3-4 p = 0.031; Mutant allele carriers: decreased platinum resistance in 60 patients34
OR 1.61, 1.04-2.50 Heterozygous variant allele carriers compared to homozygous wildtype allele carriers: increased risk on severe neutropenia and increased likelihood of overall survival following cisplatin-gemcitabine in 104 patients32
ERCC2 rs1799793 c.934G > A Decreased need for colony stimulating factor p = 0.042; Heterozygous variant allele carriers compared to homozygous wildtype allele carriers: increased severity of neutropenia following cisplatin-cyclophosphamide in 104 patients32
OR 0.63, 0.41-0.98
Decreased platinum free interval p = 0.016,
HR = 0.75, 0.60-0.95